Conversely, population studies have found no association between increased risk of diabetic retinopathy and GLP-1 RA use [104, 105], with a low odds ratio observed for exenatide (OR 0.16), liraglutide (OR 0.18), albiglutide (OR 0.09), and dulaglutide (OR 0.11) [106]
Prior authorization for GLP-1 medications is typically required regardless of plan type
This review explores the mechanisms, clinical development, and therapeutic potential of these novel agents, excluding already approved drugs like liraglutide, semaglutide, and tirzepatide
Regulators protecting patients in the news The FDA posted letters warning drug manufacturing companies in Connecticut and Missouri to correct sterility issues in their production of over-the-counter drug products
The peptide cost calculator can also help you compare the true per-dose cost of different providers and concentrations
Cardiovascular disease and risk management: standards of care in diabetes2025